Bridgebio Pharma Inc (BBIO)

$49.08 -1.15 (-2.29%)
Market Cap 9.38B
Revenue (ttm) 221.90M
Net Income (ttm) -535.76M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -241.44%
Debt to Equity Ratio -1.04
Volume 1,490,100
Avg Vol 2,962,124
Day's Range N/A - N/A
Shares Out 191.17M
Stochastic %K 38%
Beta 1.23
Analysts Strong Sell
Price Target $62.38

Company Profile

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 doub...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 391 9740
Address:
3160 Porter Drive, Suite 250, Palo Alto, United States
BIOTECH_GURU
BIOTECH_GURU Aug. 24 at 9:07 PM
$BBIO Three P3 readouts will exponentially reduce burn rate. Will keep holding for continued rise. Biotech is rate sensitive so I expect biotechs to make a comeback over the next 6-12 months.
1 · Reply
BioTechHealthX
BioTechHealthX Aug. 24 at 2:45 PM
$BBIO BridgeBio’s pipeline looks strong, but its rising expenses and insider sales raise red flags. Is BBIO headed for a crash? https://biotechhealthx.com/biotech-news/bbio-stock-alert-can-bridgebio-pharma-survive-its-cash-burn/
0 · Reply
Papermoon347
Papermoon347 Aug. 24 at 1:43 PM
$BBIO Junkenmiller sold (there Loss) CEO and CFO sold a total of 85,000 shares, big deal CEO still owns close to a million shares plus warren's etc. Everybody deserves to be rewarded, and let's not forget only one reason why you buy a stock and millions of reasons why you sell it hopefully that's the last of the selling ,and we get a wave of positive news going forward.
0 · Reply
MachineLeverage
MachineLeverage Aug. 23 at 7:00 AM
$BBIO BridgeBio Pharma Inc is a clinical stage genetic disease company with multiple pivotal readouts
2 · Reply
Papermoon347
Papermoon347 Aug. 22 at 2:54 PM
$BBIO Hopefully it finishes like a champ today .
0 · Reply
TwongStocks
TwongStocks Aug. 21 at 2:16 PM
$BBIO They have a dedicated page now for $BBOT https://stocktwits.com/symbol/BBOT
0 · Reply
IPOtweet
IPOtweet Aug. 21 at 12:04 AM
Two de-SPACs defy trends to raise $100 million with low redemptions $KYIV $BBIO $IPO #IPO https://zpr.io/HmDGaXWi7qXW
0 · Reply
Papermoon347
Papermoon347 Aug. 19 at 6:08 PM
$BBIO Nice two minutes ago , i said it would be nice to see green ,then wow !
0 · Reply
Jblack500
Jblack500 Aug. 19 at 1:03 PM
$BBIO moving avg supports 20 day 47.51. 50 day 45.00
0 · Reply
Jblack500
Jblack500 Aug. 18 at 8:09 PM
$BBIO if pullback continues may look to add at 47.50...just some gains being digested right now. Nothing to be nervous about
0 · Reply
Latest News on BBIO
‘BUY THAT THING': Historically undervalued stock now has value, says wealth expert

Aug 19, 2025, 5:30 PM EDT - 5 days ago

‘BUY THAT THING': Historically undervalued stock now has value, says wealth expert

BridgeBio Pharma, Inc. (BBIO) Q2 2025 Earnings Call Transcript

Aug 9, 2025, 4:30 AM EDT - 15 days ago

BridgeBio Pharma, Inc. (BBIO) Q2 2025 Earnings Call Transcript

BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates

Aug 5, 2025, 4:01 PM EDT - 19 days ago

BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates

Biotech Has Been Stalling. 3 Stocks That Could See Healthy Gains.

Jul 30, 2025, 12:37 PM EDT - 25 days ago

Biotech Has Been Stalling. 3 Stocks That Could See Healthy Gains.

AMGN INSM

Novel Human Genetics Evidence Confirms Estimates of Genetic Prevalence, Underdiagnosis, and Potentially Greater Symptom Burden of Gain-of-Function CASR Variants Associated with ADH1

Jul 23, 2025, 7:30 AM EDT - 4 weeks ago

Novel Human Genetics Evidence Confirms Estimates of Genetic Prevalence, Underdiagnosis, and Potentially Greater Symptom Burden of Gain-of-Function CASR Variants Associated with ADH1

BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET

Jul 22, 2025, 7:30 AM EDT - 4 weeks ago

BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET

It is time for a move higher in biotech, says Mizuho's Jared Holz

Jul 7, 2025, 6:29 PM EDT - 6 weeks ago

It is time for a move higher in biotech, says Mizuho's Jared Holz

BMRN GILD INSM XBI

BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty

Jun 30, 2025, 7:30 AM EDT - 7 weeks ago

BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty

BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET

Jun 26, 2025, 7:30 AM EDT - 2 months ago

BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET

BridgeBio: New Data Bolsters The Bull Case

Jun 4, 2025, 3:34 AM EDT - 2 months ago

BridgeBio: New Data Bolsters The Bull Case

BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 2, 2025, 7:30 AM EDT - 2 months ago

BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM

May 20, 2025, 7:30 AM EDT - 3 months ago

Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM

Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study

May 19, 2025, 12:33 PM EDT - 3 months ago

Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 14, 2025, 4:01 PM EDT - 3 months ago

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study

May 13, 2025, 7:30 AM EDT - 3 months ago

First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study

BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC

May 12, 2025, 7:30 AM EDT - 3 months ago

BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC

BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025

May 7, 2025, 7:30 AM EDT - 3 months ago

BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025

BridgeBio Pharma, Inc. (BBIO) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 9:43 PM EDT - 4 months ago

BridgeBio Pharma, Inc. (BBIO) Q1 2025 Earnings Call Transcript

BridgeBio Reports First Quarter 2025 Financial Results and Business Updates

Apr 29, 2025, 4:01 PM EDT - 4 months ago

BridgeBio Reports First Quarter 2025 Financial Results and Business Updates

BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM

Apr 28, 2025, 5:00 AM EDT - 4 months ago

BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM

BridgeBio: Early Signs Point To Blockbuster Revenues

Apr 22, 2025, 11:14 AM EDT - 4 months ago

BridgeBio: Early Signs Point To Blockbuster Revenues

BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET

Apr 22, 2025, 7:30 AM EDT - 4 months ago

BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET

Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM

Mar 31, 2025, 10:00 AM EDT - 5 months ago

Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM

Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug

Mar 27, 2025, 3:20 PM EDT - 5 months ago

Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug

AZN

Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM

Mar 27, 2025, 7:00 AM EDT - 5 months ago

Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM

BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions

Mar 24, 2025, 7:30 AM EDT - 5 months ago

BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions

BridgeBio Announces CFO Succession

Mar 17, 2025, 4:01 PM EDT - 5 months ago

BridgeBio Announces CFO Succession

BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt

Feb 26, 2025, 2:49 AM EST - 6 months ago

BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt

BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt

Feb 24, 2025, 4:09 PM EST - 6 months ago

BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt

BridgeBio: Strong Start For Attruby

Feb 20, 2025, 1:34 PM EST - 6 months ago

BridgeBio: Strong Start For Attruby

BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update

Feb 20, 2025, 7:30 AM EST - 6 months ago

BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update

BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025

Feb 13, 2025, 4:01 PM EST - 6 months ago

BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025

BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CM

Feb 11, 2025, 9:21 AM EST - 6 months ago

BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CM

Top 4 Health Care Stocks You May Want To Dump In Q1

Jan 21, 2025, 6:06 AM EST - 7 months ago

Top 4 Health Care Stocks You May Want To Dump In Q1

BSX ISRG ITCI

BridgeBio Pharma Is A Buy On Dips After Attruby's FDA Approval

Jan 15, 2025, 9:30 AM EST - 7 months ago

BridgeBio Pharma Is A Buy On Dips After Attruby's FDA Approval

BridgeBio CEO Neil Kumar: Our heart disease drug staves off death and hospitalization

Jan 14, 2025, 3:40 PM EST - 7 months ago

BridgeBio CEO Neil Kumar: Our heart disease drug staves off death and hospitalization

BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones

Jan 13, 2025, 11:00 AM EST - 7 months ago

BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones

Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market

Jan 8, 2025, 11:13 AM EST - 8 months ago

Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market

AMGN BMY IOVA LLY MDGL MRK PFE

BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference

Jan 8, 2025, 7:30 AM EST - 8 months ago

BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference

Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Dec 13, 2024, 7:18 AM EST - 9 months ago

Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Unnatural Products Announces BridgeBio Exercises Option to License Macrocyclic Therapeutics for Development in Rare Diseases and Oncology

Dec 3, 2024, 8:00 AM EST - 9 months ago

Unnatural Products Announces BridgeBio Exercises Option to License Macrocyclic Therapeutics for Development in Rare Diseases and Oncology

FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market

Nov 25, 2024, 9:03 AM EST - 9 months ago

FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market

PFE

BridgeBio: Next Chapter Begins After Attruby Approval

Nov 24, 2024, 3:48 PM EST - 9 months ago

BridgeBio: Next Chapter Begins After Attruby Approval

US FDA approves BridgeBio's drug for rare heart condition

Nov 22, 2024, 7:25 PM EST - 9 months ago

US FDA approves BridgeBio's drug for rare heart condition

Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

Nov 22, 2024, 7:11 PM EST - 9 months ago

Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market

Nov 19, 2024, 2:44 PM EST - 9 months ago

BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market

Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

Nov 18, 2024, 11:15 AM EST - 9 months ago

Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

BridgeBio Oncology Therapeutics (BBOT) Appoints Praveen Tipirneni, MD, to its Board of Directors as Non-Executive Director

Nov 18, 2024, 8:00 AM EST - 9 months ago

BridgeBio Oncology Therapeutics (BBOT) Appoints Praveen Tipirneni, MD, to its Board of Directors as Non-Executive Director

BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia

Nov 18, 2024, 5:30 AM EST - 9 months ago

BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia

BIOTECH_GURU
BIOTECH_GURU Aug. 24 at 9:07 PM
$BBIO Three P3 readouts will exponentially reduce burn rate. Will keep holding for continued rise. Biotech is rate sensitive so I expect biotechs to make a comeback over the next 6-12 months.
1 · Reply
BioTechHealthX
BioTechHealthX Aug. 24 at 2:45 PM
$BBIO BridgeBio’s pipeline looks strong, but its rising expenses and insider sales raise red flags. Is BBIO headed for a crash? https://biotechhealthx.com/biotech-news/bbio-stock-alert-can-bridgebio-pharma-survive-its-cash-burn/
0 · Reply
Papermoon347
Papermoon347 Aug. 24 at 1:43 PM
$BBIO Junkenmiller sold (there Loss) CEO and CFO sold a total of 85,000 shares, big deal CEO still owns close to a million shares plus warren's etc. Everybody deserves to be rewarded, and let's not forget only one reason why you buy a stock and millions of reasons why you sell it hopefully that's the last of the selling ,and we get a wave of positive news going forward.
0 · Reply
MachineLeverage
MachineLeverage Aug. 23 at 7:00 AM
$BBIO BridgeBio Pharma Inc is a clinical stage genetic disease company with multiple pivotal readouts
2 · Reply
Papermoon347
Papermoon347 Aug. 22 at 2:54 PM
$BBIO Hopefully it finishes like a champ today .
0 · Reply
TwongStocks
TwongStocks Aug. 21 at 2:16 PM
$BBIO They have a dedicated page now for $BBOT https://stocktwits.com/symbol/BBOT
0 · Reply
IPOtweet
IPOtweet Aug. 21 at 12:04 AM
Two de-SPACs defy trends to raise $100 million with low redemptions $KYIV $BBIO $IPO #IPO https://zpr.io/HmDGaXWi7qXW
0 · Reply
Papermoon347
Papermoon347 Aug. 19 at 6:08 PM
$BBIO Nice two minutes ago , i said it would be nice to see green ,then wow !
0 · Reply
Jblack500
Jblack500 Aug. 19 at 1:03 PM
$BBIO moving avg supports 20 day 47.51. 50 day 45.00
0 · Reply
Jblack500
Jblack500 Aug. 18 at 8:09 PM
$BBIO if pullback continues may look to add at 47.50...just some gains being digested right now. Nothing to be nervous about
0 · Reply
Papermoon347
Papermoon347 Aug. 18 at 2:48 PM
$BBIO Why ? Just sellers and shorts ?
0 · Reply
Papermoon347
Papermoon347 Aug. 18 at 2:10 PM
$BBIO We can use another is miracle close today .
0 · Reply
Jblack500
Jblack500 Aug. 15 at 8:12 PM
$BBIO your brain is the size of a walnut if you think i was spreading fear uncertainty and doubt on bbio before er. Do you live in an alternate reality where you create your own false narrative?
0 · Reply
RonIsWrong
RonIsWrong Aug. 15 at 6:06 PM
$BBIO took some profits off today.
2 · Reply
Reanimated666
Reanimated666 Aug. 15 at 2:11 PM
$BBIO Taking 25 percent gains here Largely outperformed $EXEL and more than recovered any losses i occurred
1 · Reply
BIOTECH_GURU
BIOTECH_GURU Aug. 15 at 1:52 PM
$BBIO for every share of BBIO you indirectly own 35% of BBOT. BBOT may become a 10B company by end of P2.
1 · Reply
Reanimated666
Reanimated666 Aug. 15 at 11:17 AM
$BBIO @Stocktwits we are 53 cents?!?!?
2 · Reply
heweg11
heweg11 Aug. 15 at 10:59 AM
$BBIO $SNDX
0 · Reply
Reanimated666
Reanimated666 Aug. 14 at 7:44 PM
$BBIO climb back to new highs
0 · Reply
Papermoon347
Papermoon347 Aug. 14 at 2:52 PM
$BBIO Bulls ,this stock changed my life ,lost good money with it a couple years ago , then they had a private placement for a million shares @$27( I believe), i said to myself if it's good for them it's good for me @$27 ,anyway we suffered enough , so we all deserve it and thank you all for your insights it helped me stay in the game .
0 · Reply
Papermoon347
Papermoon347 Aug. 14 at 2:32 PM
$BBIO I always thought this might happen but when it happens you're in awe !
1 · Reply
Pika_Capital
Pika_Capital Aug. 14 at 2:23 PM
$BBIO what a beauty.
0 · Reply